SCM Life Sciences Completes Patient Recruitment for Phase 2 Clinical Trial of Atopic Dermatitis Treatment

[Asia Economy Reporter Lee Gwan-joo] SCM Life Sciences announced on the 13th that it has completed the recruitment of clinical patients for the Phase 2 clinical trial of the atopic dermatitis stem cell therapy 'SCM-AGH' and has administered the first dose.

This Phase 2 clinical trial began recruiting subjects from a total of 15 university hospitals, including Inha University Hospital, starting in February last year, and completed recruitment of 72 patients in 14 months. The Phase 2 trial aims to verify the efficacy and safety of the treatment in patients with moderate to severe atopic dermatitis.

The company plans to complete all patient visits by October, conduct a comprehensive analysis of the efficacy and safety of SCM-AGH, and finalize the report by around April next year. They will focus on confirming the efficacy of the clinical drug by observing the change in the 'EASI score' (an evaluation score measuring the severity of atopic dermatitis) compared to baseline at 12 weeks after SCM-AGH administration.

An SCM Life Sciences official stated, “Based on the results of the Phase 2 trial, we plan to obtain approval for the Phase 3 clinical trial plan (IND) next year and proceed with the domestic Phase 3 trial and product approval through Handok.”

This content was produced with the assistance of AI translation services.